{"id":"CU23330","slug":"targeted-cdkn2a-suppression--CU23330","source":{"id":"CU23330","dataset":"techtransfer","title":"Targeted Cdkn2a Suppression Therapy to Prevent Muscle Stem Cell Aging in SMA and Myopathies","description_":"<p>This technology is a gene-targeting therapeutic approach that suppresses Cdkn2a expression to prevent premature muscle stem cell aging for spinal muscular atrophy (SMA) and other myopathies.</p>\r\r<h2>Unmet Need: Improving muscle preservation in SMA and myopathy therapies</h2>\r\r<p>The current standard of care for spinal muscular atrophy (SMA) primarily focuses on restoring survival motor neuron (SMN) protein levels, which addresses motor neuron dysfunction but fails to adequately target muscle degeneration caused by intrinsic muscle stem cell defects. Without addressing these defects, disease progression persists, leading to diminished therapeutic outcomes and quality of life. There is a critical need for treatments that directly preserve muscle function and prevent degeneration to complement existing SMA therapies and more effectively combat myopathy.</p>\r\r<h2>The Technology: Targeted Cdkn2a suppression to prevent muscle degeneration</h2>\r\r<p>This technology leverages gene-targeting interventions, such as siRNAs and Gapmers, to suppress Cdkn2a expression, effectively reducing RNA and protein levels associated with muscle stem cell senescence. By restoring the self-renewal capacity of muscle satellite cells, it prevents premature aging and exhaustion of these cells, addressing a key contributor to muscle degeneration in conditions like SMA and other myopathies.</p>\r\r<p>This technology has been validated in mice models.</p>\r\r<h2>Applications:</h2>\r\r<ul>\r<li>Therapeutics for SMA and other myopathies</li>\r<li>Drug screening for Cdkn2a-related muscle stem cell senescence</li>\r<li>Combine therapy involving SMN protein restoration and Cdkn2a suppression</li>\r<li>Research tool for investigating the role of Cdkn2a in muscle stem cell biology</li>\r<li>Studying muscle regeneration mechanisms in degenerative diseases</li>\r</ul>\r\r<h2>Advantages:</h2>\r\r<ul>\r<li>Complementary approach</li>\r<li>Broad applicability</li>\r<li>Non-invasive delivery potential</li>\r<li>Cost-effective</li>\r</ul>\r\r<h2>Lead Inventor:</h2>\r\r<p><a href=\"https://www.pathology.columbia.edu/profile/umrao-monani-phd\">Umrao R. Monani, Ph.D.</a></p>\r\r<h2>Patent Information:</h2>\r\r<p>Patent Pending(<a href=\"https://patentcenter.uspto.gov/applications/19422180\">US19/422,180</a>)</p>\r\r<p>Patent Pending(<a href=\"https://patentscope2.wipo.int/search/en/detail.jsf?docId=WO2024263971&amp;_gid=202452\">WO/2024/263971</a>)</p>\r\r<h2>Related Publications:</h2>\r\r<ul>\r<li><a href=\"https://pubmed.ncbi.nlm.nih.gov/36863345/\">Kim JK, Jha NN, Awano T, Caine C, Gollapalli K, Welby E, Kim SS, Fuentes-Moliz A, Wang X, Feng Z, Sera F, Takeda T, Homma S, Ko CP, Tabares L, Ebert AD, Rich MM, Monani UR. “A spinal muscular atrophy modifier implicates the SMN protein in SNARE complex assembly at neuromuscular synapses” Neuron. 2023 May 3; 111(9): 1423-1439.</a></li>\r</ul>\r\r<h2>Tech Ventures Reference:</h2>\r\r<ul>\r<li><p>IR CU23330</p></li>\r<li><p>Licensing Contact: <a href=\"mailto:techtransfer@columbia.edu\">Kristin Neuman</a> </p></li>\r</ul>\r","tags":["High-throughput screening","Myopathy","Neuron","P16","Protein","SNARE (protein)","Small interfering RNA","Spinal muscular atrophy","Stem cell"],"file_number":"CU23330","collections":[{"key":426,"name":"Gene Therapy"}],"meta_description":"Gene-targeted Cdkn2a suppression preserves muscle stem cell renewal, complementing SMN therapies for SMA and myopathies.","apriori_judge_output":"{\"scores\":{\"novelty\":4.0,\"potential_impact\":4.0,\"readiness\":3.0,\"scalability\":3.0,\"timeliness\":4.0},\"weighted_score\":3.9,\"risks\":[\"Biological safety and off-target effects of Cdkn2a suppression\",\"Delivery challenges across muscle types and patients\",\"Regulatory uncertainty for gene-targeting senescence pathways\",\"Intellectual property and freedom-to-operate considerations\",\"Translational gap from mouse models to SMA/myopathy patients\"],\"one_sentence_take\":\"Strong novelty and timely potential with meaningful impact, but readiness and scalability require careful navigation of safety, delivery, and regulatory hurdles.\"}","inventors":["Narendra Jha","Umrao R. Monani Ph.D."],"manager":"Kristin Neuman","depts":["Neurology","Pathology & Cell Biology"],"divs":["Columbia University Medical Center (CUMC)"],"date_released":"2025-01-30"},"highlight":{},"matched_queries":null,"score":0.0}